Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Page 1
Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease.
Colombo C, Crosignani A, Alicandro G, Zhang W, Biffi A, Motta V, Corti F, Setchell KDR. Colombo C, et al. Among authors: crosignani a. J Pediatr. 2016 Oct;177:59-65.e1. doi: 10.1016/j.jpeds.2016.05.008. Epub 2016 Jun 11. J Pediatr. 2016. PMID: 27297203
The aim was to specifically focus on the extent of biotransformation of UDCA to its hepatotoxic metabolite, lithocholic acid, because of recent concerns regarding the safety of long-term, high-dose UDCA treatment for CFLD. STUDY DESIGN: Twenty patients with CFLD (median ag …
The aim was to specifically focus on the extent of biotransformation of UDCA to its hepatotoxic metabolite, lithocholic acid, because of rec …
Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study.
Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, de Franchis R, Almasio PL, Maisonneuve P. Bruno S, et al. Among authors: crosignani a. Hepatology. 2010 Jun;51(6):2069-76. doi: 10.1002/hep.23528. Hepatology. 2010. PMID: 20196120
The incidence of de novo development of esophageal varices (EV) in patients with compensated liver cirrhosis has been determined by few studies in the short term and never in the long term. The aims of the present study were to determine the incidence and the risk f …
The incidence of de novo development of esophageal varices (EV) in patients with compensated liver cirrhosis has been determined by few stud …
Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies.
Larghi A, Zuin M, Crosignani A, Ribero ML, Pipia C, Battezzati PM, Binelli G, Donato F, Zanetti AR, Podda M, Tagger A. Larghi A, et al. Among authors: crosignani a. Hepatology. 2002 Oct;36(4 Pt 1):993-1000. doi: 10.1053/jhep.2002.36129. Hepatology. 2002. PMID: 12297849
In conclusion, our homogeneous cohort showed a wide spectrum of clinical, virologic and histologic features, and, more importantly, short-term outcome differed noticeably despite the common source of infection....
In conclusion, our homogeneous cohort showed a wide spectrum of clinical, virologic and histologic features, and, more importantly, short- …
Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients.
Battezzati PM, Zuin M, Crosignani A, Allocca M, Invernizzi P, Selmi C, Villa E, Podda M. Battezzati PM, et al. Among authors: crosignani a. Aliment Pharmacol Ther. 2001 Sep;15(9):1427-34. doi: 10.1046/j.1365-2036.2001.01018.x. Aliment Pharmacol Ther. 2001. PMID: 11552915 Free article. Clinical Trial.
BACKGROUND: Combined medical treatment may provide further benefit to primary biliary cirrhosis (PBC) patients administered ursodeoxycholic acid (UDCA). AIM: To evaluate the long-term effects of colchicine and UDCA in symptomatic PBC patients. ...
BACKGROUND: Combined medical treatment may provide further benefit to primary biliary cirrhosis (PBC) patients administered ursodeoxycholic …
Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C.
Bruno S, Battezzati PM, Bellati G, Manzin A, Maggioni M, Crosignani A, Borzio M, Solforosi L, Morabito A, Ideo G, Podda M. Bruno S, et al. Among authors: crosignani a. J Hepatol. 2001 May;34(5):748-55. doi: 10.1016/s0168-8278(01)00062-9. J Hepatol. 2001. PMID: 11434622
CONCLUSIONS: Most sustained, virological responders without cirrhosis normalize liver histology in the long-term and are cured of the disease. Sustained responders remaining viremic still show histological improvement, albeit to a lesser extent....
CONCLUSIONS: Most sustained, virological responders without cirrhosis normalize liver histology in the long-term and are cured of the …
Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease.
Colombo C, Crosignani A, Battezzati PM, Castellani MR, Comi S, Melzi ML, Giunta A. Colombo C, et al. Among authors: crosignani a. J Hepatol. 1999 Oct;31(4):672-7. doi: 10.1016/s0168-8278(99)80347-x. J Hepatol. 1999. PMID: 10551391
Therefore, patients with impaired biliary drainage are expected to obtain the greatest benefit from this treatment. METHODS: We evaluated the effects of long-term treatment with ursodeoxycholic acid in 36 patients with cystic fibrosis-associated liver disease, and compared …
Therefore, patients with impaired biliary drainage are expected to obtain the greatest benefit from this treatment. METHODS: We evaluated th …
Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis.
Invernizzi P, Setchell KD, Crosignani A, Battezzati PM, Larghi A, O'Connell NC, Podda M. Invernizzi P, et al. Among authors: crosignani a. Hepatology. 1999 Feb;29(2):320-7. doi: 10.1002/hep.510290220. Hepatology. 1999. PMID: 9918905 Clinical Trial.
This comparative study suggests that tauroursodeoxycholate has significant advantages over ursodeoxycholate that may be of benefit for long-term therapy in PBC....
This comparative study suggests that tauroursodeoxycholate has significant advantages over ursodeoxycholate that may be of benefit for long- …
Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study.
Crosignani A, Budillon G, Cimino L, Del Vecchio Blanco C, Loguercio C, Ideo G, Raimondo G, Stabilini R, Podda M. Crosignani A, et al. Hepatogastroenterology. 1998 Sep-Oct;45(23):1624-9. Hepatogastroenterology. 1998. PMID: 9840118 Clinical Trial.
CONCLUSIONS: Tauroursodeoxycholic acid improves the biochemical expression of chronic hepatitis. Long-term studies with clinically relevant end-points are warranted....
CONCLUSIONS: Tauroursodeoxycholic acid improves the biochemical expression of chronic hepatitis. Long-term studies with clinically re …
17 results